IGHM Antikörper (AA 45-178)

Produktnummer ABIN7156089

Produktdetails anti-IGHM Antikörper

Target: IGHM (Immunoglobulin Heavy Constant mu (IGHM))

Bindungsspezifität: AA 45-178

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IGHM Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), Western Blotting (WB), ELISA

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Immunoglobulin heavy constant mu protein (45-178AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: WB:1:500-1:5000, IHC:1:500-1:1000,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu IGHM

Target: IGHM (Immunoglobulin Heavy Constant mu (IGHM))

Andere Bezeichnung: IGHM (IGHM Produkte)

Synonyme: AI326478 antikoerper, Igh-6 antikoerper, Igh-M antikoerper, Igh6 antikoerper, Igm antikoerper, muH antikoerper, ighm1 antikoerper, wu:fj14a08 antikoerper, zgc:101769 antikoerper, AGM1 antikoerper, MU antikoerper, VH antikoerper, immunoglobulin heavy constant mu antikoerper, Ighm antikoerper, ighm antikoerper, IGHM antikoerper

Hintergrund:

Background: Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268). IgM antibodies play an important role in primary defense mechanisms. They have been shown to be involved in early recognition of external invaders like bacteria and viruses, cellular waste and modified self, as well as in recognition and elimination of precancerous and cancerous lesions. The membrane-bound form is found in the majority of normal B-cells alongside with IgD. Membrane-bound IgM induces the phosphorylation of CD79A and CD79B by the Src family of protein tyrosine kinases. It may cause death of cells by apoptosis. It is also found in soluble form, which represents about 30 % of the total serum immunoglobulins where it is found almost exclusively as a homopentamer. After the antigen binds to the B-cell receptor, the secreted form is secreted in large amounts (PubMed:3137579, PubMed:16895553).

Aliases: IGHMImmunoglobulin heavy constant mu antibody, Ig mu chain C region antibody, Ig mu chain C region BOT antibody, Ig mu chain C region GAL antibody, Ig mu chain C region OU antibody

UniProt: P01871